AGWCA
BTAI icon

Annis Gardner Whiting Capital Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210 Buy
156
+44
+39% +$72 ﹤0.01% 1270
2025
Q4 		$180 Buy
+112
New +$231 ﹤0.01% 1175

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Annis Gardner Whiting Capital Advisors's BTAI Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors increased its BioXcel Therapeutics (BTAI) stake by 39% in Q1 2026, buying an estimated $72 and bringing the position to 156 shares worth $210. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Annis Gardner Whiting Capital Advisors first reported a position in BTAI in Q4 2025 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors held 156 shares of BioXcel Therapeutics worth $210 as of Q1 2026.
  • Annis Gardner Whiting Capital Advisors bought 44 BioXcel Therapeutics shares in Q1 2026, an estimated $72.
  • BioXcel Therapeutics made up ﹤0.01% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #1270 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in BioXcel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.